2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4239 Pre-onset cytokine profiles predict Occurrence and severity of acute graft-versus-host disease and survival after allo-HSCT

Dongchu Wang, MD, Liyuan Qiu, MD2, Hui Wang IV, MD3
1 Hebei Yanda Lu Daopei Hospital, Langfang, China
2 Hebei Yanda Lu Daopei Hospital, Langfang, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, China

Background

Early prediction of acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is critical for accurate risk stratification. Nevertheless, existing research on the dynamic changes of cytokines prior to acute GVHD onset remains insufficient.

Methods

This study enrolled 75 patients diagnosed with T-cell acute lymphoblastic leukemia (T-ALL) who received allo-HSCT in Hebei Yanda Ludaopei Hospital between February 2021 and February 2025. 35 patients developed acute GVHD, with a median onset of 34 days for the first occurrence of GVHD and 44 days for GVHD reaching the maximum grade. 24 cytokines were measured during the post-transplantation period. Only pre-onset data were included in the analysis for the GVHD group, while the follow-up data of the non-GVHD group was limited to the scale of the longest days of GVHD onset event in the cohort. Patients were classified due to the maximum GVHD grade into two subgroups: 0-I (including patients without GVHD) and II-IV for severity analysis. Wilcoxon tests, logistic regression, and receiver operating characteristic (ROC) curves were used to evaluate the correlations between cytokine levels and GVHD occurrence, severity, and survival outcomes.

Results

GVHD occurrence

7 cytokines with statistically significant differences (p<0.05). The concentrations of IL-8, Elafin, MIP-1α, and IL-22 were significantly lower in patients who developed GVHD, while the concentrations of ST-2, sCD25, and IL-12p70 were significantly higher in this cohort. After adjustment via logistic regression, ST-2 (β=1.52×10?4, p<0.001) and Elafin (β=-8.43×10?5, p=0.003) remained statistically significance. ROC analysis demonstrated that IL-8 yielded the highest area under the curve (AUC=0.67); when the cutoff value was set at 4.63 pg/ml, the negative predictive value (NPV) was 83.2% and the positive predictive value (PPV) was 46.4%. The AUCs of Elafin and ST-2 were 0.62 and 0.61, and the NPVs of both indicators were close to 80%.

GVHD severity

8 cytokines with statistically significant differences (p<0.05): MIP-1α, Elafin, MCP-1, IL-15, IFN-γ, GM-CSF, IL-10, and ST-2. The concentrations of MIP-1α, Elafin, MCP-1, IL-15, and IFN-γ were lower in the severe GVHD subgroup, while the concentrations of ST-2, GM-CSF, and IL-10 were significantly elevated. Logistic regression confirmed that MIP-1α (β=-0.058, p<0.001) and Elafin (β=-9.07×10?5, p=0.001) were protective factors against severe GVHD, while ST-2 (β=8.74×10?5, p=0.018) was a risk factor for severe GVHD. MIP-1α exhibited the highest AUC (0.65), followed by Elafin (0.64), with NPVs of both indicators around 80%; the AUCs of MCP-1, IL-15, and IFN-γ ranged from 0.61 to 0.62.

Survival prediction

9 cytokines showed statistically significant differences between deceased and surviving patients (p<0.05), including IL-10, TNFRI, IL-8, Granzyme B, and sCD25. The median concentrations of IL-10 (3.65 pg/mL vs. 0.73 pg/mL, p=3.9×10?6) and TNFRI (1922 pg/mL vs. 1128 pg/mL, p=3.0×10?4) were significantly higher in deceased group, while the concentrations of Granzyme B, IL-17A, and IL-12p70 were significantly lower in this cohort. Logistic regression indicated that TNFRI (β=5.15×10?4, p<0.001), GM-CSF (β=0.014, p=0.006), and IL-5 (β=0.095, p=0.012) were  risk factors for post-transplant mortality, and ST-2 (β=9.36×10?5, p=0.049) also showed a significant positive correlation with mortality. IL-10 achieved the highest AUC (0.739), followed by TNFRI (0.687).

Elevated ST-2 concentrations prior to GVHD onset were consistently correlated with increased GVHD occurrence, higher GVHD severity, and elevated post-transplant mortality. Reduced concentrations of Elafin and MIP-1α were associated with an increased risk of severe GVHD, which may reflect the early consumption of molecules with protective functions. Elevated IL-10 and TNFRI concentrations showed the closest association with end-stage post-transplant mortality.

 Conclusion

Cytokine profiles in the early post-transplantation period can predict the occurrence and severity of aGVHD. Increased ST-2 level indicates elevated GVHD risk and poor survival prognosis; reduced Elafin and MIP-1α levels are associated with development of severe GVHD; elevated IL-10 and TNFRI levels indicate increased risk of end-stage mortality. Combined dynamic monitoring of multiple cytokines may contribute to improved risk stratification and clinical management of patients after allo-HSCT.

Hui Wang IV, MD: No relevant conflicts of interest to declare.